Ji-Guang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ji-Guang Wang has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Jan A. Staessen
Department of Cardiovascular Medicine, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
8 shared publications Yan Li
Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Ctr Epidemiol Studies & Clin Trials, Shanghai 200030, Peoples R China
6 shared publications- Giuseppe Bianchi
Chair of Nephrology, Vita e Salute University, S Raffaele Hospital, Milano, Italy
2 shared publications Lisheng Liu
Beijing Hypertension Institute Chinese Hypertension League, Beijing, China
2 shared publicationsMichel Safar
From the Centre for Epidemiological Studies and Clinical Trials (J.G.W., Y.L.), Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Preventive Cardiology Program (S.S.F.), University of California, Irvine; and the Diagnosis Center (M.S.), Hopital Hotel-Dieu, Paris, France
2 shared publicationsRobert Fagard
2 shared publications
Latest Publications
- Open Access
- 23 March 2012
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 12 (1) , 34
Individual patient data meta-analysis of survival data using Poisson regression models
Background: An Individual Patient Data (IPD) meta-analysis is often considered the gold-standard for synthesising survival data from clinical trials. An IPD meta-analysis can be achieved by either a two-stage or a one-stage approach, depending on whether the trials are analysed separately or simultaneously. A range of one-stage hierarchical Cox models have been previously proposed, but these are known to be computationally intensive and are not currently available in all standard statistical software. We describe an alternative approach using Poisson based Generalised Linear Models (GLMs).Methods: We illustrate, through application and simulation, the Poisson approach both classically and in a Bayesian framework, in two-stage and one-stage approaches. We outline the benefits of our one-stage approach through extension to modelling treatment-covariate interactions and non-proportional hazards. Ten trials of hypertension treatment, with all-cause death the outcome of interest, are used to apply and assess the approach.Results: We show that the Poisson approach obtains almost identical estimates to the Cox model, is additionally computationally efficient and directly estimates the baseline hazard. Some downward bias is observed in classical estimates of the heterogeneity in the treatment effect, with improved performance from the Bayesian approach.Conclusion: Our approach provides a highly flexible and computationally efficient framework, available in all standard statistical software, to the investigation of not only heterogeneity, but the presence of non-proportional hazards and treatment effect modifiers.
- 23 March 2012
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 12 (1) , 34
Open AccessIndividual patient data meta-analysis of survival data using Poisson regression models
Background: An Individual Patient Data (IPD) meta-analysis is often considered the gold-standard for synthesising survival data from clinical trials. An IPD meta-analysis can be achieved by either a two-stage or a one-stage approach, depending on whether the trials are analysed separately or simultaneously. A range of one-stage hierarchical Cox models have been previously proposed, but these are known to be computationally intensive and are not currently available in all standard statistical software. We describe an alternative approach using Poisson based Generalised Linear Models (GLMs).Methods: We illustrate, through application and simulation, the Poisson approach both classically and in a Bayesian framework, in two-stage and one-stage approaches. We outline the benefits of our one-stage approach through extension to modelling treatment-covariate interactions and non-proportional hazards. Ten trials of hypertension treatment, with all-cause death the outcome of interest, are used to apply and assess the approach.Results: We show that the Poisson approach obtains almost identical estimates to the Cox model, is additionally computationally efficient and directly estimates the baseline hazard. Some downward bias is observed in classical estimates of the heterogeneity in the treatment effect, with improved performance from the Bayesian approach.Conclusion: Our approach provides a highly flexible and computationally efficient framework, available in all standard statistical software, to the investigation of not only heterogeneity, but the presence of non-proportional hazards and treatment effect modifiers.
- 1 January 2009
- Published by Taylor & Francis in Blood Pressure
- Vol. 18 (1-2) , 17-22
Baseline characteristics of participants in the Hypertension in the Very Elderly Trial (HYVET)
The Hypertension in the Very Elderly Trial (HYVET) is a randomized double‐blind trial of active antihypertensive treatment (indapamide 1.5 mg sustained release ±2—4 mg perindopril) vs placebo in participants over the age of 80 years with a systolic blood pressure (SBP) of 160–199 mmHg during a placebo run‐in period plus a diastolic blood pressure (DBP) of<110 mmHg. The trial has completed with 3845 subjects randomized and we report the baseline characteristics. The participants were a healthy group. The numbers smoking, drinking alcohol and having previous cardiovascular events were low, and their hypertensive status was not usually associated with the metabolic syndrome; 1.0% of the whole group had a total cholesterol over 8.0 mmol/l, 1.1% a blood sugar over 11.1 mmol/l (irrespective of anti‐diabetic treatment) and 1.7% a serum urate over 460 μmol/l (women) and 0.6% over 520 μmol/l (men). A serum creatinine over 150 μmol/l excluded participants from the trial. The gender differences and age comparisons were as expected but the women had higher average total and high‐density‐lipoprotein‐cholesterol blood concentrations. Those with prior cardiovascular disease had an excess of the known cardiovascular risk factors. The baseline characteristics provide a basis for further understanding of the HYVET results, which have been published recently.
- 1 January 2009
- Published by Taylor & Francis in Blood Pressure
- Vol. 18 (1-2) , 17-22
Baseline characteristics of participants in the Hypertension in the Very Elderly Trial (HYVET)
The Hypertension in the Very Elderly Trial (HYVET) is a randomized double‐blind trial of active antihypertensive treatment (indapamide 1.5 mg sustained release ±2—4 mg perindopril) vs placebo in participants over the age of 80 years with a systolic blood pressure (SBP) of 160–199 mmHg during a placebo run‐in period plus a diastolic blood pressure (DBP) of<110 mmHg. The trial has completed with 3845 subjects randomized and we report the baseline characteristics. The participants were a healthy group. The numbers smoking, drinking alcohol and having previous cardiovascular events were low, and their hypertensive status was not usually associated with the metabolic syndrome; 1.0% of the whole group had a total cholesterol over 8.0 mmol/l, 1.1% a blood sugar over 11.1 mmol/l (irrespective of anti‐diabetic treatment) and 1.7% a serum urate over 460 μmol/l (women) and 0.6% over 520 μmol/l (men). A serum creatinine over 150 μmol/l excluded participants from the trial. The gender differences and age comparisons were as expected but the women had higher average total and high‐density‐lipoprotein‐cholesterol blood concentrations. Those with prior cardiovascular disease had an excess of the known cardiovascular risk factors. The baseline characteristics provide a basis for further understanding of the HYVET results, which have been published recently.
- 1 November 2008
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 26 (11) , 2161-2167
Anthropometric and metabolic phenotypes in relation to the ADRA2B deletion/insertion polymorphism in Chinese population
Objective To investigate whether the ADRA2B D/I polymorphism is associated with anthropometric, metabolic, and blood pressure phenotypes in a Chinese population. Methods In 1306 participants enrolled in the JingNing population study, we measured anthropometry, blood pressure, plasma glucose, and serum lipids, and genotyped the ADRA2B D/I polymorphism. We defined overweight (BMI >= 25 kg/m(2)) and obesity (BMI >= 30 kg/m(2)) according to the WHO criteria. Results Genotype frequencies of the ADRA2B D/I polymorphism were significantly (P=0.02) different between 228 (17.5%) overweight and obese participants and 1078 normal weight participants, but similar between 317 (24.3%) hypertensive participants and 989 normotensive participants. After adjustment for covariates, the ADRA2B DD compared with II homozygotes had significantly (P <= 0.01) lower BMI (21.9 versus 22.5 kg/m(2)), waist-to-hip ratio (0.835 versus 0.847), and triceps skinfold thickness (1.18 versus 1.27 cm) and had a significantly lower risk of overweight and obesity (odds ratio 0.52, 95% confidence interval, 0.49-0.54, P=0.0001). Further analyses showed significant (P <= 0.01) interaction between the ADRA2B D/I polymorphism and physical activity in relation to BMI and waist-to-hip ratio. In physically less active participants [energy expenditure <= 3386 kcal/day median)], DD compared with II homozygotes had lower BMI, waist-to-hip ratio and risk of overweight and obesity by 0.6 kg/m(2), 0.012 and 60.6%, respectively. Conclusion The ADRA2B D allele is associated with a favourable anthropometric and metabolic profile in Chinese population, especially in physically less active participants. J Hypertens 26: 2161-2167 (c) 2008 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
- 1 November 2008
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 26 (11) , 2161-2167
Anthropometric and metabolic phenotypes in relation to the ADRA2B deletion/insertion polymorphism in Chinese population
Objective To investigate whether the ADRA2B D/I polymorphism is associated with anthropometric, metabolic, and blood pressure phenotypes in a Chinese population. Methods In 1306 participants enrolled in the JingNing population study, we measured anthropometry, blood pressure, plasma glucose, and serum lipids, and genotyped the ADRA2B D/I polymorphism. We defined overweight (BMI >= 25 kg/m(2)) and obesity (BMI >= 30 kg/m(2)) according to the WHO criteria. Results Genotype frequencies of the ADRA2B D/I polymorphism were significantly (P=0.02) different between 228 (17.5%) overweight and obese participants and 1078 normal weight participants, but similar between 317 (24.3%) hypertensive participants and 989 normotensive participants. After adjustment for covariates, the ADRA2B DD compared with II homozygotes had significantly (P <= 0.01) lower BMI (21.9 versus 22.5 kg/m(2)), waist-to-hip ratio (0.835 versus 0.847), and triceps skinfold thickness (1.18 versus 1.27 cm) and had a significantly lower risk of overweight and obesity (odds ratio 0.52, 95% confidence interval, 0.49-0.54, P=0.0001). Further analyses showed significant (P <= 0.01) interaction between the ADRA2B D/I polymorphism and physical activity in relation to BMI and waist-to-hip ratio. In physically less active participants [energy expenditure <= 3386 kcal/day median)], DD compared with II homozygotes had lower BMI, waist-to-hip ratio and risk of overweight and obesity by 0.6 kg/m(2), 0.012 and 60.6%, respectively. Conclusion The ADRA2B D allele is associated with a favourable anthropometric and metabolic profile in Chinese population, especially in physically less active participants. J Hypertens 26: 2161-2167 (c) 2008 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
- Open Access
- 1 June 2008
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 21 (6) , 668-673
Reference Values for the Arterial Pulse Wave in Chinese
Background. Pulse wave analysis using the SphygmoCor system allows the estimation of central pulse pressure (PP) and peripheral and central augmentatio
- 1 June 2008
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 21 (6) , 668-673
Open AccessReference Values for the Arterial Pulse Wave in Chinese
Background. Pulse wave analysis using the SphygmoCor system allows the estimation of central pulse pressure (PP) and peripheral and central augmentatio
- 1 December 2007
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 25 (12) , 2398-2405
Anthropometric and lifestyle factors associated with white-coat, masked and sustained hypertension in a Chinese population
Objective We investigated to what extent anthropometric and lifestyle factors contributed to the classification of Chinese individuals into groups with white-coat, masked and sustained hypertension (HT). Methods We measured the office and ambulatory blood pressure (BP) in 694 Chinese enrolled in the JingNing population study (45.7% men; mean age, 48.4 years). In multivariate-adjusted analyses, we determined the correlates of both types of BP and the factors contributing to white-coat HT (conventional and daytime BP ≥140/90 and 2) and urinary sodium (OR, 1.18 per 50 mmol/day), but was inversely associated with urinary potassium (OR, 0.34 per 25 mmol/day). Furthermore, the risk of white-coat and masked HT increased with age (OR, 1.79 and 1.40, respectively) and body mass index (OR, 1.14 and 1.12). Women were less likely to have masked hypertension than men (OR, 0.39). Conclusions Sex, age, body mass index, and urinary sodium and potassium excretion contribute to the risk of white-coat, masked and sustained HT in Chinese.
- 1 December 2007
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 25 (12) , 2398-2405
Anthropometric and lifestyle factors associated with white-coat, masked and sustained hypertension in a Chinese population
Objective We investigated to what extent anthropometric and lifestyle factors contributed to the classification of Chinese individuals into groups with white-coat, masked and sustained hypertension (HT). Methods We measured the office and ambulatory blood pressure (BP) in 694 Chinese enrolled in the JingNing population study (45.7% men; mean age, 48.4 years). In multivariate-adjusted analyses, we determined the correlates of both types of BP and the factors contributing to white-coat HT (conventional and daytime BP ≥140/90 and 2) and urinary sodium (OR, 1.18 per 50 mmol/day), but was inversely associated with urinary potassium (OR, 0.34 per 25 mmol/day). Furthermore, the risk of white-coat and masked HT increased with age (OR, 1.79 and 1.40, respectively) and body mass index (OR, 1.14 and 1.12). Women were less likely to have masked hypertension than men (OR, 0.39). Conclusions Sex, age, body mass index, and urinary sodium and potassium excretion contribute to the risk of white-coat, masked and sustained HT in Chinese.
- Open Access
- 1 July 2007
- Published by Wolters Kluwer Health in Hypertension
- Vol. 50 (1) , 181-188
Prevention of Stroke and Myocardial Infarction by Amlodipine and Angiotensin Receptor Blockers
In the present quantitative overview of outcome trials, we investigated the efficacy of amlodipine or angiotensin receptor blockers in the prevention of stroke and myocardial infarction in patients with hypertension, coronary artery disease, or diabetic nephropathy. The analysis included 12 trials of 94 338 patients. The analysis of trials involving an amlodipine group showed that amlodipine provided more protection against stroke and myocardial infarction than other antihypertensive drugs, including angiotensin receptor blockers (−19%, P P =0.03) and placebo (−37%, P =0.06 and −29%, P =0.04). The analysis of trials involving an angiotensin receptor blocker group showed contrasting results between trials versus amlodipine and trials versus other antihypertensive drugs for stroke (+19% versus −25%; P P =0.03). The results of 3 trials comparing an angiotensin receptor blocker with placebo were neutral ( P ≥0.14). The within-trial between-group difference in achieved systolic pressure ranged from −1.1 to +4.7 mm Hg for trials involving an amlodipine group and from −2.8 to +4.0 mm Hg for trials involving an angiotensin receptor blocker group. The metaregression analysis correlating odds ratios with blood pressure differences showed a negative relationship (regression coefficients: −3% to −8%), which reached statistical significance (regression coefficient: −6%; P =0.01) for stroke in trials involving an amlodipine group. In conclusion, blood pressure differences largely accounted for cardiovascular outcome.
- 1 July 2007
- Published by Wolters Kluwer Health in Hypertension
- Vol. 50 (1) , 181-188
Open AccessPrevention of Stroke and Myocardial Infarction by Amlodipine and Angiotensin Receptor Blockers
In the present quantitative overview of outcome trials, we investigated the efficacy of amlodipine or angiotensin receptor blockers in the prevention of stroke and myocardial infarction in patients with hypertension, coronary artery disease, or diabetic nephropathy. The analysis included 12 trials of 94 338 patients. The analysis of trials involving an amlodipine group showed that amlodipine provided more protection against stroke and myocardial infarction than other antihypertensive drugs, including angiotensin receptor blockers (−19%, P P =0.03) and placebo (−37%, P =0.06 and −29%, P =0.04). The analysis of trials involving an angiotensin receptor blocker group showed contrasting results between trials versus amlodipine and trials versus other antihypertensive drugs for stroke (+19% versus −25%; P P =0.03). The results of 3 trials comparing an angiotensin receptor blocker with placebo were neutral ( P ≥0.14). The within-trial between-group difference in achieved systolic pressure ranged from −1.1 to +4.7 mm Hg for trials involving an amlodipine group and from −2.8 to +4.0 mm Hg for trials involving an angiotensin receptor blocker group. The metaregression analysis correlating odds ratios with blood pressure differences showed a negative relationship (regression coefficients: −3% to −8%), which reached statistical significance (regression coefficient: −6%; P =0.01) for stroke in trials involving an amlodipine group. In conclusion, blood pressure differences largely accounted for cardiovascular outcome.
- 1 July 2006
- Published by Wolters Kluwer Health in Stroke
- Vol. 37 (7) , 1933-1940
Carotid Intima-Media Thickness and Antihypertensive Treatment
Background and Purpose— Hypertension promotes carotid intima-media thickening. We reviewed the randomized controlled trials that evaluated the effects of an antihypertensive drug versus placebo or another antihypertensive agent of a different class on carotid intima-media thickness. Methods— We searched the PubMed and the Web of Science databases for randomized clinical trials, published in English before 2005, and included 22 trials. Results— In 8 trials including 3329 patients with diabetes or coronary heart disease, antihypertensive treatment initiated with an angiotensin-converting enzyme (ACE) inhibitor, a β-blocker, or a calcium-channel blocker (CCB), compared with placebo or no-treatment, reduced the rate of intima-media thickening by 7 μm/year ( P =0.01). In 9 trials including 4564 hypertensive patients, CCBs, ACE inhibitors, an angiotensin II receptor blocker or an α-blocker, compared with diuretics or β-blockers, in the presence of similar blood pressure reductions, decreased intima-media thickening by 3 μm/year ( P =0.03). The overall beneficial effect of the newer over older drugs was largely attributable to the decrease of intima-media thickening by 5 μm/year ( P =0.007) in 4 trials of CCBs involving 3619 patients. In 5 trials including 287 patients with hypertension or diabetes, CCBs compared with ACE inhibitors did not differentially affect blood pressure, but attenuated intima-media thickening by 23 μm/year ( P =0.02). The treatment induced changes in carotid intima-media thickness correlated with the changes in lumen diameter ( P =0.02), but not with the differences in achieved blood pressure ( P >0.53). Conclusions— CCBs reduce carotid intima-media thickening. This mechanism might contribute to their superior protection against stroke.
- 1 July 2006
- Published by Wolters Kluwer Health in Stroke
- Vol. 37 (7) , 1933-1940
Carotid Intima-Media Thickness and Antihypertensive Treatment
Background and Purpose— Hypertension promotes carotid intima-media thickening. We reviewed the randomized controlled trials that evaluated the effects of an antihypertensive drug versus placebo or another antihypertensive agent of a different class on carotid intima-media thickness. Methods— We searched the PubMed and the Web of Science databases for randomized clinical trials, published in English before 2005, and included 22 trials. Results— In 8 trials including 3329 patients with diabetes or coronary heart disease, antihypertensive treatment initiated with an angiotensin-converting enzyme (ACE) inhibitor, a β-blocker, or a calcium-channel blocker (CCB), compared with placebo or no-treatment, reduced the rate of intima-media thickening by 7 μm/year ( P =0.01). In 9 trials including 4564 hypertensive patients, CCBs, ACE inhibitors, an angiotensin II receptor blocker or an α-blocker, compared with diuretics or β-blockers, in the presence of similar blood pressure reductions, decreased intima-media thickening by 3 μm/year ( P =0.03). The overall beneficial effect of the newer over older drugs was largely attributable to the decrease of intima-media thickening by 5 μm/year ( P =0.007) in 4 trials of CCBs involving 3619 patients. In 5 trials including 287 patients with hypertension or diabetes, CCBs compared with ACE inhibitors did not differentially affect blood pressure, but attenuated intima-media thickening by 23 μm/year ( P =0.02). The treatment induced changes in carotid intima-media thickness correlated with the changes in lumen diameter ( P =0.02), but not with the differences in achieved blood pressure ( P >0.53). Conclusions— CCBs reduce carotid intima-media thickening. This mechanism might contribute to their superior protection against stroke.
- 1 April 2006
- Published by Elsevier in Kidney International
- Vol. 69 (7) , 1153-1158
Blood pressure and urinary sodium excretion in relation to the A-1984G adrenomedullin polymorphism in a Chinese population
- 1 April 2006
- Published by Elsevier in Kidney International
- Vol. 69 (7) , 1153-1158
Blood pressure and urinary sodium excretion in relation to the A-1984G adrenomedullin polymorphism in a Chinese population
- Open Access
- 27 January 2005
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 19 (4) , 293-299
Gender-specific association between pulse pressure and C-reactive protein in a Chinese population
There is growing evidence that low-grade chronic inflammation, as reflected by the raised serum concentration of C-reactive protein, might be a risk factor for hypertension, in particular in women. We therefore investigated gender-specific associations of systolic and diastolic blood pressure and pulse pressure with serum C-reactive protein concentration in a Chinese population sample. In 463 participants, we measured serum C-reactive protein concentration using a high-sensitivity immunonephelometric latex-enhanced assay. We performed single and multiple linear regression analyses. The 224 male and 239 female subjects were of similar age (51.0 years) and had similar levels of systolic blood pressure (124.7 mmHg) and pulse pressure (47.1 mmHg), but men, compared with women, had higher diastolic blood pressure (79.6 vs 75.8 mmHg; P0.10; P=0.02 for interaction between gender and serum C-reactive protein). In women, with one-fold increase in serum C-reactive protein concentration, pulse pressure was 1.94 mmHg higher. The categorical analyses confirmed our findings. With similar adjustments applied, women in the fourth quartile, compared with those in the lowest quartile, had a 7.6 mmHg higher pulse pressure (95% confidence interval 3.5–11.7 mmHg; P=0.0003). Furthermore, when women were analysed according to menopausal status, the association between pulse pressure and C-reactive protein was only significant in postmenopausal (P0.04), but not in premenopausal, subjects (P0.21). In conclusion, taken together with the previous gender-specific observations on carotid lesions and hypertension, our finding suggests that chronic low-grade inflammation might play a role in the widening of pulse pressure in Chinese women. This cross-sectional observation warrants further investigation in prospective studies.
- 27 January 2005
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 19 (4) , 293-299
Open AccessGender-specific association between pulse pressure and C-reactive protein in a Chinese population
There is growing evidence that low-grade chronic inflammation, as reflected by the raised serum concentration of C-reactive protein, might be a risk factor for hypertension, in particular in women. We therefore investigated gender-specific associations of systolic and diastolic blood pressure and pulse pressure with serum C-reactive protein concentration in a Chinese population sample. In 463 participants, we measured serum C-reactive protein concentration using a high-sensitivity immunonephelometric latex-enhanced assay. We performed single and multiple linear regression analyses. The 224 male and 239 female subjects were of similar age (51.0 years) and had similar levels of systolic blood pressure (124.7 mmHg) and pulse pressure (47.1 mmHg), but men, compared with women, had higher diastolic blood pressure (79.6 vs 75.8 mmHg; P0.10; P=0.02 for interaction between gender and serum C-reactive protein). In women, with one-fold increase in serum C-reactive protein concentration, pulse pressure was 1.94 mmHg higher. The categorical analyses confirmed our findings. With similar adjustments applied, women in the fourth quartile, compared with those in the lowest quartile, had a 7.6 mmHg higher pulse pressure (95% confidence interval 3.5–11.7 mmHg; P=0.0003). Furthermore, when women were analysed according to menopausal status, the association between pulse pressure and C-reactive protein was only significant in postmenopausal (P0.04), but not in premenopausal, subjects (P0.21). In conclusion, taken together with the previous gender-specific observations on carotid lesions and hypertension, our finding suggests that chronic low-grade inflammation might play a role in the widening of pulse pressure in Chinese women. This cross-sectional observation warrants further investigation in prospective studies.
- 1 November 2004
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 4 (6) , 1023-1031
Primary and secondary prevention of stroke by antihypertensive drug treatment
Hypertension is the most powerful risk factor for stroke. Antihypertensive drug treatment reduces the incidence of stroke. In a meta-analysis of actively controlled trials, calcium-channel blockers, including (-8%; p = 0.07) or excluding verapamil (-10%; p = 0.02), as well as angiotensin Type 1 receptor blockers (-24%; p = 0.0002) resulted in better stroke prevention than the old drugs (diuretics or beta-blockers), whereas the opposite trend was observed for angiotensin-converting enzyme inhibitors (+10%; p = 0.03). An overview of six trials conducted in patients with a history of cerebrovascular disease demonstrated that blood pressure-lowering therapy reduced stroke recurrence by 25% (p = 0.004). A meta-regression analysis showed that within-trial differences in systolic blood pressure accounted for the prevention of stroke in most trials. This finding was corroborated by the recently published Valsartan Antihypertensive Long-term Use Evaluation trial.
- 1 November 2004
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 4 (6) , 1023-1031
Primary and secondary prevention of stroke by antihypertensive drug treatment
Hypertension is the most powerful risk factor for stroke. Antihypertensive drug treatment reduces the incidence of stroke. In a meta-analysis of actively controlled trials, calcium-channel blockers, including (-8%; p = 0.07) or excluding verapamil (-10%; p = 0.02), as well as angiotensin Type 1 receptor blockers (-24%; p = 0.0002) resulted in better stroke prevention than the old drugs (diuretics or beta-blockers), whereas the opposite trend was observed for angiotensin-converting enzyme inhibitors (+10%; p = 0.03). An overview of six trials conducted in patients with a history of cerebrovascular disease demonstrated that blood pressure-lowering therapy reduced stroke recurrence by 25% (p = 0.004). A meta-regression analysis showed that within-trial differences in systolic blood pressure accounted for the prevention of stroke in most trials. This finding was corroborated by the recently published Valsartan Antihypertensive Long-term Use Evaluation trial.